Pharmacotherapy Department, School of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Pharmacotherapy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Phytother Res. 2018 Jul;32(7):1382-1387. doi: 10.1002/ptr.6073. Epub 2018 Mar 9.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and is potentially treatable, though there are few therapeutic agents available. Artichoke leaf extract (ALE) has shown potential as a hepatoprotective agent. This study sought to determine if ALE had therapeutic utility in patients with established NAFLD. In this randomized double-blind placebo-controlled parallel-group trial, 100 subjects with ultrasound-diagnosed NAFLD were randomized to either ALE 600 mg daily or placebo for a 2-month period. NAFLD response was assessed by liver ultrasound and serological markers including the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio and AST to platelet ratio index (APRI) score. Ninety patients completed the study (49 ALE and 41 placebo) with no side effects reported. ALE treatment compared with placebo: Doppler sonography showed increased hepatic vein flow (p < .001), reduced portal vein diameter (p < .001) and liver size (p < .001), reduction in serum ALT (p < .001) and AST (p < .001) levels, improvement in AST/ALT ratio and APRI scores (p < .01), and reduction in total bilirubin. ALE supplementation reduced total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and triglyceride concentrations (p = .01). This study has shown beneficial effects of ALE supplementation on both ultrasound liver parameters and liver serum parameters (ALT, AST, APRI ratio, and total bilirubin) in patients with NAFLD.
非酒精性脂肪性肝病 (NAFLD) 是全球最常见的慢性肝病病因，尽管目前可用的治疗药物有限，但该病具有潜在的可治疗性。朝鲜蓟叶提取物 (ALE) 已显示出作为一种肝保护剂的潜力。本研究旨在确定 ALE 在已确诊的非酒精性脂肪性肝病患者中是否具有治疗作用。在这项随机、双盲、安慰剂对照的平行组试验中，100 名经超声诊断为非酒精性脂肪性肝病的患者被随机分为 ALE 600mg 每日组或安慰剂组，疗程为 2 个月。通过肝脏超声和血清学标志物（包括天冬氨酸转氨酶 [AST]/丙氨酸转氨酶 [ALT] 比值和 AST 与血小板比值指数 [APRI] 评分）评估非酒精性脂肪性肝病的应答。90 例患者完成了研究（49 例 ALE 和 41 例安慰剂），未报告不良反应。与安慰剂相比，ALE 治疗：多普勒超声显示肝静脉血流增加（p<0.001），门静脉直径（p<0.001）和肝脏大小（p<0.001）减小，血清 ALT（p<0.001）和 AST（p<0.001）水平降低，AST/ALT 比值和 APRI 评分改善（p<0.01），总胆红素降低。ALE 补充剂可降低总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和甘油三酯浓度（p=0.01）。本研究表明，ALE 补充剂对非酒精性脂肪性肝病患者的超声肝脏参数和血清肝脏参数（ALT、AST、APRI 比值和总胆红素）均有有益作用。
